A detailed history of Graham Capital Management, L.P. transactions in Erasca, Inc. stock. As of the latest transaction made, Graham Capital Management, L.P. holds 36,410 shares of ERAS stock, worth $79,373. This represents 0.0% of its overall portfolio holdings.

Number of Shares
36,410
Previous 24,955 45.9%
Holding current value
$79,373
Previous $53,000 41.51%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$1.67 - $2.55 $19,129 - $29,210
11,455 Added 45.9%
36,410 $75,000
Q4 2023

Feb 14, 2024

SELL
$1.67 - $2.49 $10,477 - $15,622
-6,274 Reduced 20.09%
24,955 $53,000
Q3 2023

Nov 22, 2023

SELL
$1.97 - $2.91 $54,553 - $80,583
-27,692 Reduced 47.0%
31,229 $61,000
Q2 2023

Aug 14, 2023

BUY
$2.57 - $3.3 $124,372 - $159,700
48,394 Added 459.71%
58,921 $162,000
Q1 2023

May 15, 2023

BUY
$2.74 - $4.44 $28,843 - $46,739
10,527 New
10,527 $31,000

Others Institutions Holding ERAS

About Erasca, Inc.


  • Ticker ERAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,147,000
  • Market Cap $266M
  • Description
  • Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...
More about ERAS
Track This Portfolio

Track Graham Capital Management, L.P. Portfolio

Follow Graham Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Graham Capital Management, L.P. with notifications on news.